Sponsored by Merck 26 Jan 2022 Top Reasons to Outsource Your Early Clinical Pipeline to a CDMO …free guidebook to navigate through the important considerations necessary to successfully bring a molecule to the clinic. *The Life Science business of Merck operates as MilliporeSigma in the United States… January 26, 2022 - 8 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 AUM LifeTech secures $400,000 grant for lung cancer immunotherapy program …United States continues to be at the forefront of biomedical innovation, technology, and business due to immigrant founders and leaders like Veenu, who leave no stone unturned and persevere even… August 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2017 Interview: Why Asian CROs are Turning to the European Biotech Market …of their customer base in the United States. As their coverage of the US has become more comprehensive, they are now looking for markets that are less well covered. A… November 30, 2017 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2025 iGEM Jamboree: leap into the synthetic biology future Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, working… November 13, 2025 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2017 Edwin Moses on how Ablynx has made it to the top of European biotech …and supportive investors in the US. But what we probably miss a little bit is the talent that exists in the United States, where they’ve had so many years of… December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019 Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience …and focused on rare diseases. There are 7,000 rare diseases that affect 60 million people in Europe and the United States, but only 5% have treatments today. These often affect… August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Nov 2024 Seven miRNA-focused companies pioneering new therapies in 2024 …grant for the development of CTX-002 for the treatment of progressive inflammatory lung disorders. In October 2023, the same program was awarded $3.8 million from the United States Department of… November 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus …the implementation of Beyfortus. “We have seen the recent spikes in RSV cases around the world, including in the United States, which underscore the need for a preventative option against… November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 FDA clears insulin pen medical device …heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates… December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2018 Women’s Health Biotech Raises €28M to Fund Phase II Menopause Drug Trial …team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide who suffer debilitating symptoms of the menopause.”… August 29, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2020 UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients …Covid-19 program. Roivant Sciences is also seeking regulatory approval to trial its phase II-ready GM-CSF-targeting antibody, gimsilumab, in Covid-19 patients in the United States, Europe, and Asia. Image from Shutterstock… April 6, 2020 - 2 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
Sponsored by OXGENE 26 Oct 2021 Plasmids: How to Solve a Bottleneck in Scalable Gene Therapy Manufacturing? …the building blocks of viral vectors, remain a bottleneck in gene therapy manufacturing. Two companies have united to provide exciting alternatives. With over 2,400 gene therapies in the global pipeline… October 26, 2021 - 7 minutesmins - By Letícia Manosso Share WhatsApp Twitter Linkedin Email